SEIZALAM Drug Patent Profile
✉ Email this page to a colleague
When do Seizalam patents expire, and what generic alternatives are available?
Seizalam is a drug marketed by MMT and is included in one NDA.
The generic ingredient in SEIZALAM is midazolam hydrochloride. There are nine drug master file entries for this compound. Twenty-six suppliers are listed for this compound. Additional details are available on the midazolam hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Seizalam
A generic version of SEIZALAM was approved as midazolam hydrochloride by FRESENIUS KABI USA on June 20th, 2000.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for SEIZALAM?
- What are the global sales for SEIZALAM?
- What is Average Wholesale Price for SEIZALAM?
Summary for SEIZALAM
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 36 |
Clinical Trials: | 1 |
Patent Applications: | 1,069 |
Formulation / Manufacturing: | see details |
What excipients (inactive ingredients) are in SEIZALAM? | SEIZALAM excipients list |
DailyMed Link: | SEIZALAM at DailyMed |
![SEIZALAM drug patent expirations Drug patent expirations by year for SEIZALAM](/p/graph/s/t/SEIZALAM-patent-expirations.png)
Recent Clinical Trials for SEIZALAM
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Rafa Laboratories | Phase 1 |
Ology Bioservices | Phase 1 |
Joint Project Management Office for Chemical, Biological, Radiological, and Nuclear Medical | Phase 1 |
Pharmacology for SEIZALAM
Drug Class | Benzodiazepine |
US Patents and Regulatory Information for SEIZALAM
SEIZALAM is protected by zero US patents and one FDA Regulatory Exclusivity.
FDA Regulatory Exclusivity protecting SEIZALAM
TREATMENT OF STATUS EPILEPTICUS IN ADULTS
Exclusivity Expiration: ⤷ Sign Up
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mmt | SEIZALAM | midazolam hydrochloride | SOLUTION;INTRAMUSCULAR | 209566-001 | Sep 14, 2018 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |